Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye membrane patch shows promise for blinding corneal disease

NCT ID NCT05909735

Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a thin, clear membrane from the back of the cornea (Descemet's membrane) can help the eye heal in people with limbal stem cell deficiency, a condition that can cause blindness. Nineteen participants received the membrane as a patch on the eye's surface. The goal was to see if the membrane could help regrow the cornea's outer layer and improve vision, while monitoring for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

19 people

The number who actually took part.

Started

Nov 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Arm 1: * partial LSCD (involving less than 75% of the limbus, or \<75% of the corneal surface) * Visually significant (best-corrected visually acuity 20/100 or worse) Arm 2: * total/near-total LSCD with recurrent erosions or PEDs (involving more than 75% of the limbus, or more than 75% of the corneal surface) * Visually significant (best-corrected visually acuity 20/100 or worse) PLUS * Persistent epithelial defects last \>2 weeks despite maximal medical therapy OR * Recurrent erosions occuring at least once every month Exclusion Criteria: * Pregnant women * Prisoners (vulnerable population) * Adults lacking capacity to consent (vulnerable population) * Adults unable to sign consent due to non-english speaking or illiterate (vulnerable population)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congenital aniridia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aniridia limbal stem cell deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Congenital aniridia Limbal stem cell deficiency

Contacts and locations

Locations

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.